New York, New York--(Newsfile Corp. - November 11, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Molina Healthcare, Inc. ("Molina Healthcare, Inc.") (NYSE: MOH) concerning possible violations of federal securities laws.On October 23, 2025, Molina published its third quarter, fiscal 2025 earnings well below consensus and slashed its guidance for the third time this year, citing cost pressure and underperformance. The Company is now expecting earnings of $14 per share ...

Core Insights - Teladoc Health, Inc. (TDOC) shares have decreased by 8.9% following the release of its third-quarter 2025 results, primarily due to a decline in access fee revenues, U.S. revenues, and weaker performance in the BetterHelp segment, although this was partially mitigated by strong international revenue growth and reduced expenses [1] Financial Performance - The adjusted loss per share for Q3 2025 was 21 cents, which was narrower than the Zacks Consensus Estimate of a 26-cent loss but wider than the 19-cent loss from the previous year [2] - Operating revenues fell by 2% year over year to $626.4 million, although this figure exceeded the consensus estimate by 0.2% [2] - Access fee revenues decreased by 6% year over year to $520.9 million, missing the Zacks Consensus Estimate of $534 million [3] - Other revenues increased by 24% year over year to $105.5 million, surpassing the consensus estimate of $91 million [3] Geographical Revenue Breakdown - U.S. revenues totaled $509.8 million, down 5% year over year, falling short of the Zacks Consensus Estimate of $521 million [4] - International revenues rose by 12% year over year to $116.7 million, exceeding the consensus estimate of $105 million [4] Expense Management - Total costs and expenses decreased by 1% year over year to $678.4 million, which was lower than the estimate of $691.4 million, driven by reductions in advertising, marketing, technology, and administrative expenses [5] Segment Performance - The Integrated Care segment's revenues grew by 2% year over year to $389.5 million, beating the consensus estimate [6] - The BetterHelp segment's revenues fell by 8% year over year to $236.9 million, missing the consensus estimate [7] Membership and Visits - Total visits to Teladoc Health reached 4.1 million, a 1% increase year over year, surpassing the consensus estimate of 4 million [8] - U.S. Integrated Care Members increased by 9% year over year to 102.5 million, exceeding the consensus estimate [8] Cash Flow and Financial Position - Cash and cash equivalents at the end of Q3 2025 were $726.2 million, down 44.1% from the end of 2024 [10] - Net cash from operations was $99.3 million, a decrease of 9.9% year over year [11] - Free cash flow dropped by 14% year over year to $67.9 million [11] Future Outlook - For Q4 2025, Integrated Care segment revenues are expected to grow by 1-5.2% year over year, while BetterHelp segment revenues are projected to decline by 8.8-3.8% [12] - Total revenues for Q4 are anticipated to be between $622 million and $652 million [13] - For the full year 2025, total revenues are now expected to be between $2.510 billion and $2.539 billion, with an adjusted EBITDA forecast of $270-$287 million [16]

Core Insights - Centene Corporation reported Q3 results that exceeded expectations, leading to an upward revision of the full-year outlook to at least $2 [2] - The company is making progress in Medicaid Health Benefits Ratio (HBR) sequentially [2] Medicaid Updates - Centene was not awarded the CMS Florida contract, which it had held for the past six years, despite a strong response in the RFP process [3] - The company was unable to agree on terms for the new contract, aligning with its strategy to maintain sustainable margins [3]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Market Overview - Wall Street experienced a rally as the U.S. Senate made progress toward ending the government shutdown, which was crucial for restoring the flow of official data and improving investor sentiment [1][11] - The S&P 500 rose 1.5% to 6,832.43, the Nasdaq Composite surged 2.3% to 23,527.17, and the Dow Jones Industrial Average advanced 0.8% to 47,368.63 [2] Focus on Financially Resilient Stocks - Companies are often evaluated based on sales and earnings, but these metrics alone may not provide a complete picture of financial health [3] - A critical analysis of a company's financial background, particularly the Interest Coverage Ratio, is essential for informed investment decisions [4][7] - The Interest Coverage Ratio indicates a company's ability to pay interest on its debt, with a higher ratio suggesting a stronger financial position [5][8] Interest Coverage Ratio Insights - The Interest Coverage Ratio is calculated as Earnings before Interest & Taxes (EBIT) divided by Interest Expense [5] - A ratio below 1.0 indicates potential default risk, while a higher ratio suggests the company can withstand financial hardships [9] - Companies with strong interest coverage ratios highlighted include Life Time Group Holdings, Inc. (LTH), Cardinal Health, Inc. (CAH), McKesson Corporation (MCK), and Flowserve Corporation (FLS) [11] Company Performance Highlights - Life Time Group has a Zacks Rank of 2, with projected sales growth of 13.7% and EPS growth of 51.6% for the current financial year [16] - Cardinal Health also holds a Zacks Rank of 2, with sales and EPS growth estimates of 15.2% and 18.8%, respectively, and a significant stock increase of 66.3% over the past year [17] - McKesson Corporation, with a Zacks Rank of 2, anticipates sales and EPS growth of 13.8% and 15.6%, but has seen a stock decline of 16.1% in the past year [18] - Flowserve, also ranked 2, projects sales growth of 4.9% and EPS growth of 31.2%, with a stock increase of 15.3% over the past year [19]

Core Viewpoint - CVS Health has shown significant recovery and growth in stock performance, rising 75% this year after a challenging 2024 where it fell over 43% [1][2] Company Performance - The company replaced its CEO last year, leading to improved performance and investor sentiment [3][7] - CVS's adjusted earnings per share for Q3 were $1.60, surpassing analyst expectations of $1.37, with revenue reaching $102.9 billion, an 8% increase compared to expectations of $98.9 billion [6] Valuation and Investment Appeal - Despite the stock's significant rise, CVS remains attractively valued, trading at a price-to-earnings (P/E) multiple of 22, which drops to less than 11 on a forward earnings basis [9] - The stock's trailing P/E appears high due to a $5.7 billion goodwill impairment charge, but the forward P/E provides a clearer picture of its valuation [9] - CVS's dividend yield stands at 3.4%, significantly higher than the S&P 500 average of 1.1%, making it an appealing option for income-focused investors [12]

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. to secure legal counsel before the December 2, 2025 deadline for a securities class action lawsuit related to undisclosed adverse facts affecting the company's financial guidance and operations [1][5]. Group 1: Class Action Details - The class period for the lawsuit is from February 5, 2025, to July 23, 2025, and investors who purchased securities during this time may be entitled to compensation without upfront costs [1][2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 2, 2025 [3][6]. Group 2: Allegations Against Molina Healthcare - The lawsuit alleges that Molina failed to disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a significant cut in financial guidance for fiscal year 2025 [5]. - The lawsuit asserts that the positive statements made by Molina regarding its business and prospects were materially misleading due to the undisclosed adverse facts [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Insights - Molina Healthcare, Inc. is under investigation for possible violations of federal securities laws following disappointing earnings and guidance cuts [1][2] - The company reported third quarter fiscal 2025 earnings significantly below consensus, with an expected full-year earnings of $14 per share, down from a previous estimate of "no less than $19" [2] - Molina's stock price dropped by $38.08 to open at $157.05 per share after the earnings announcement [3] Financial Performance - Molina's third quarter earnings were well below market expectations, primarily due to cost pressures and underperformance in its marketplace business [2] - The company has revised its earnings guidance for the third time in 2025, indicating ongoing financial challenges [2] Stock Market Reaction - Following the earnings report, Molina's stock experienced a significant decline, reflecting investor concerns over the company's financial outlook [3]

Core Insights - Elevance Health Foundation is launching its inaugural $5 million Patient Safety Prize aimed at enhancing patient safety and care quality [1] - The Prize will focus on improving health literacy, reducing medication errors, and preventing patient falls [1] - Applications for the Prize will open on December 9, 2025, inviting innovative solutions from changemakers [1] Summary by Categories Company Initiatives - Elevance Health Foundation is committed to advancing patient safety through the establishment of the Patient Safety Prize [1] - The initiative is part of the Community Action Leadership (CAL) program, emphasizing community engagement and leadership in health [1] Focus Areas - The Prize specifically targets three critical areas: health literacy, medication error reduction, and fall prevention among patients [1] - The goal is to develop transformational solutions that enhance safety and improve health outcomes for vulnerable populations [1]

Core Insights - Current market conditions reflect a balance between optimism due to strong earnings and potential rate cuts, and caution stemming from high tech stock valuations and uncertainty regarding Federal Reserve actions [1] - Recent market pullbacks are viewed as a normal reset rather than a significant reversal, making stock selection challenging for retail investors [1] Stock Selection Strategy - A traditional stock-picking approach focusing on sales growth is recommended, as it provides a more reliable evaluation compared to earnings metrics [2][3] - Companies with impressive sales growth and strong cash flow are prioritized, with specific screening parameters including a 5-Year Historical Sales Growth greater than industry average and cash flow exceeding $500 million [6] Key Metrics for Evaluation - Price-to-Sales (P/S) Ratio should be less than the industry average, indicating better value for each dollar of revenue [7] - Positive revisions in sales estimates compared to the industry can lead to stock price increases [7] - Operating Margin should average over 5% over the last five years, reflecting effective cost control and sales growth [8] - Return on Equity (ROE) should exceed 5%, ensuring that sales growth translates into profits [9] - Zacks Rank of 1 or 2 indicates stocks likely to outperform the market [9] Highlighted Stocks - Vertiv Holdings Co (VRT) is projected to have a sales growth rate of 27.5% for 2025 and currently holds a Zacks Rank 1 [10][12] - Universal Health Services Inc. (UHS) expects a sales growth rate of 9.7% for 2025 and also holds a Zacks Rank 1 [10][13] - Aptiv PLC (APTV) anticipates a sales increase of 2.9% in 2025, with a Zacks Rank 2 [10][14] - Ameren Corporation (AEE) has a projected sales growth of 16.2% for 2025 and carries a Zacks Rank 2 [10][15] - FirstCash Holdings, Inc. (FCFS) expects a sales growth of 5.3% in 2025 and also holds a Zacks Rank 2 [10][16]